Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: machida r. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Shimokawa T, et al. Among authors: machida r. Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22. Lung Cancer. 2023. PMID: 37156212 Free article. Clinical Trial.
Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3).
Kodaira T, Kagami Y, Machida R, Shikama N, Sekino Y, Ito Y, Ishikura S, Saito Y, Matsumoto Y, Konishi K, Murakami N, Akimoto T, Fukushima Y, Toshiyasu T, Katano A, Nagata Y, Ogawa H, Uno T, Hamamoto Y, Nishimura Y, Mizowaki T. Kodaira T, et al. Among authors: machida r. Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1118-1124. doi: 10.1016/j.ijrobp.2023.06.251. Epub 2023 Jul 5. Int J Radiat Oncol Biol Phys. 2023. PMID: 37414261 Free article. Clinical Trial.
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).
Sasaki K, Nomura M, Kato K, Sakanaka K, Ito Y, Kadota T, Machida R, Kataoka T, Minashi K, Tsubosa Y, Kajiwara T, Fukuda H, Takeuchi H, Mizowaki T, Nishimura Y, Kitagawa Y. Sasaki K, et al. Among authors: machida r. Jpn J Clin Oncol. 2024 Jan 7;54(1):103-107. doi: 10.1093/jjco/hyad137. Jpn J Clin Oncol. 2024. PMID: 37801434 Clinical Trial.
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M, Kataoka T, Fujiwara T, Tsukushi S, Takahashi M, Kobayashi E, Yamada Y, Tanaka T, Nezu Y, Hiraga H, Wasa J, Nagano A, Nakano K, Nakayama R, Hamada T, Kawano M, Torigoe T, Sakamoto A, Asanuma K, Morii T, Machida R, Sekino Y, Fukuda H, Oda Y, Ozaki T, Tanaka K. Endo M, et al. Among authors: machida r. BMC Cancer. 2023 Mar 8;23(1):219. doi: 10.1186/s12885-023-10693-w. BMC Cancer. 2023. PMID: 36890471 Free PMC article.
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T, Zenda S, Kodaira T, Kiyota N, Fujimoto Y, Wasano K, Takahashi R, Mizowaki T, Homma A, Sasaki K, Machida R, Sekino Y, Fukuda H; Japan Clinical Oncology Group Radiation Therapy Study Group; Japan Clinical Oncology Group Head and Neck Cancer Study Group. Yokota T, et al. Among authors: machida r. BMC Cancer. 2023 Nov 6;23(1):1068. doi: 10.1186/s12885-023-11503-z. BMC Cancer. 2023. PMID: 37932681 Free PMC article. Clinical Trial.
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Suzuki T, Maruyama D, Machida R, Kataoka T, Fukushima N, Takayama N, Ohba R, Omachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Yamamoto K, Kameoka Y, Kagami Y, Tabayashi T, Maruta M, Kobayashi T, Iida S, Nagai H. Suzuki T, et al. Among authors: machida r. Hematol Oncol. 2023 Aug;41(3):590-593. doi: 10.1002/hon.3103. Epub 2022 Nov 30. Hematol Oncol. 2023. PMID: 36416678 No abstract available.
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K. Okuma HS, et al. Among authors: machida r. Clin Cancer Res. 2023 Dec 15;29(24):5079-5086. doi: 10.1158/1078-0432.CCR-23-1807. Clin Cancer Res. 2023. PMID: 37819940 Free PMC article. Clinical Trial.
187 results